Prasugrel after PCI outperforms other common antiplatelet drugs

May 28, 2026 - 04:21

A new meta-analysis suggests that prasugrel may offer the best balance of benefits and risks among common antiplatelet medications used after percutaneous coronary intervention, or PCI. Researchers who analyzed data from multiple clinical trials found that patients taking prasugrel had fewer major cardiovascular events compared to those on other drugs like ticagrelor or clopidogrel.

The study, which pooled results from thousands of patients who received a coronary stent, looked at outcomes including heart attack, stroke, and stent thrombosis. Prasugrel consistently reduced these risks more effectively than its competitors. However, the drug also carries a higher bleeding risk, which has made some doctors cautious about using it broadly.

"Prasugrel provided the optimal balance between efficacy and safety," the researchers noted in their report. They emphasized that the drug's advantages were most pronounced in patients with acute coronary syndrome, such as those having a heart attack. For stable patients, the differences were smaller, and the choice of drug may depend on individual bleeding risk.

The findings reinforce current guidelines that recommend prasugrel for certain high-risk patients but also highlight the need for careful patient selection. Doctors must weigh the reduction in clotting events against the potential for serious bleeding, especially in older adults or those with a history of ulcers or stroke.

The meta-analysis did not find a significant difference in overall death rates between the drugs, but the lower rate of nonfatal heart attacks and stent failures with prasugrel was considered clinically important. Researchers called for more studies to refine which patients benefit most from each option.